TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
180 Life Sciences ( (ATNF) ) has provided an update.
On June 17, 2025, 180 Life Sciences granted stock options and restricted shares to its executives and directors, which were initially set to vest over a year. However, the company’s board approved the accelerated vesting of these awards on July 11 and 12, 2025, allowing them to vest in full. Additionally, the company extended its consulting agreement with its Chief Accounting Officer, Eric Van Lent, through December 31, 2025, and increased the termination fee. These actions are part of the company’s efforts to retain key personnel and align their interests with the company’s growth objectives.
More about 180 Life Sciences
180 Life Sciences operates in the biotechnology industry, focusing on developing therapeutics for unmet medical needs. The company primarily engages in research and development of anti-inflammatory drugs.
Average Trading Volume: 114,792
Technical Sentiment Signal: Sell
Current Market Cap: $5.47M
For detailed information about ATNF stock, go to TipRanks’ Stock Analysis page.